Allergan PLC. (AGN) Getting Somewhat Positive Press Coverage, Report Finds
Press coverage about Allergan PLC. (NYSE:AGN) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan PLC. earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.4664659881936 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Allergan plc (AGN) AO Seeing a Consistent Downtrend – Evergreen Caller (evergreencaller.com)
- Is Now the Time to Capitalize on Allergan plc (NYSE:AGN) or The Bank of Nova Scotia (NYSE:BNS)? – FLBC News (flbcnews.com)
- Black, Jewish Goldman Sachs executive sues firm for discr… (finance.yahoo.com)
- Notable Friday Option Activity: AGN, UAA, HES – Nasdaq (nasdaq.com)
- Analyzing Mylan N.V. (MYL) and Allergan PLC. (AGN) (americanbankingnews.com)
Allergan PLC. (AGN) traded down 0.35% during midday trading on Friday, reaching $223.99. 2,006,235 shares of the company’s stock traded hands. The stock has a 50-day moving average of $243.31 and a 200 day moving average of $238.68. The company has a market cap of $74.88 billion, a P/E ratio of 6.82 and a beta of 1.16. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business earned $3.35 EPS. On average, analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.25%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
AGN has been the subject of a number of analyst reports. Citigroup Inc. reaffirmed a “focus list” rating and set a $261.27 price objective (up from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Royal Bank Of Canada raised their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective for the company. in a report on Wednesday, May 10th. UBS AG reaffirmed a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $275.49.
TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Getting Somewhat Positive Press Coverage, Report Finds” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/19/allergan-plc-agn-getting-somewhat-positive-press-coverage-report-finds.html.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.